T
Thomas W. Dubensky
Researcher at Emory University
Publications - 35
Citations - 679
Thomas W. Dubensky is an academic researcher from Emory University. The author has contributed to research in topics: Antigen & Nucleic acid. The author has an hindex of 12, co-authored 35 publications receiving 657 citations.
Papers
More filters
Journal ArticleDOI
Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants:
TL;DR: Although this relatively new class of adjuvants has to date only been evaluated in mice, newly available CDN-STING cocrystal structures will likely intensify efforts in this field towards further development and evaluation in human trials both in preventive vaccine and immunotherapy settings.
Patent
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
Thomas W. Dubensky,David B. Kanne,Leong Meredith Lai Ling,Edward E. Lemmens,Glickman Laura Hix +4 more
TL;DR: In this paper, a cyclic-di-nucleotide (CDN) immune stimulator that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes).
Patent
Compositions and methods for inhibiting "stimulator of interferon gene" -dependent signalling
TL;DR: In this paper, cyclic-di-nucleotide (CDN) compounds are provided in the form of a composition comprising one or more cyclic purine dinucleotides which inhibit STING-dependent TBK1 activation and the resulting production of type I interferon.
Patent
Modified free-living microbes, vaccine compositions and methods of use thereof
TL;DR: In this paper, free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of a microbe to repair its nucleic acids.
Patent
Engineered listeria and methods of use thereof
TL;DR: In this paper, a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners, is described, and vectors for mediating site-specific recombination and removing removable antibiotic resistance genes.